

2698-617 9

NEW GENERATION VACCINES


edited by

Graeme C. Woodrow

Biotech Australia Pty. Ltd.
Sydney, New South Wales, Australia

Myron M. Levine

University of Maryland School of Medicine
Baltimore, Maryland



Marcel Dekker, Inc. • New York and Basel

Contents

<i>Preface</i>	iii
<i>Contributors</i>	xi

Part I INTRODUCTION TO VACCINOLOGY

1. Vaccines and Vaccination in the Historical Perspective <i>Myron M. Levine</i>	3
2. The Traditional Vaccines: An Overview <i>Gordon L. Ada</i>	19
3. An Overview of Biotechnology As Applied to Vaccine Development <i>Graeme C. Woodrow</i>	31
4. Initial Clinical Evaluation of New Vaccine Candidates: Phase I and Phase II Trials of Safety, Immunogenicity, and Preliminary Efficacy <i>Deirdre A. Herrington</i>	43
5. Longer Term Evaluation of Vaccine Efficacy: Methodological Issues for Phase III and Phase IV Trials <i>John D. Clemens and Bonita F. Stanton</i>	51
6. Reaping the Benefits: Getting Vaccines to Those Who Need Them <i>Ralph H. Henderson, K. Keja, Artur M. Galazka, and Carole A. Chan</i>	69

Part II MOLECULAR IMMUNOLOGY AS APPLIED TO VACCINE DEVELOPMENT

7. Immunogenicity and Immunopotentialiation <i>Gustav J. V. Nossal</i>	85
8. Immunological Introduction to the “Difficult” Diseases <i>Graham F. Mitchell</i>	95

9. Computer Prediction of T-Cell Epitopes 109
Hanah Margalit, Charles DeLisi, and Jay A. Berzofsky
10. Identification of Epitopes Through Peptide Technology 117
Allan J. Saul and H. Mario Geysen

Part III IMMUNOPOTENTIATION BY ADJUVANTS AND ALTERNATIVE PRESENTATION OF ANTIGENS

11. Adjuvants for a New Generation of Vaccines 129
Anthony C. Allison and Noelene E. Byars
12. Proteosomes, Hydrophobic Anchors, Iscoms, and Liposomes for Improved Presentation of Peptide and Protein Vaccines 141
George H. Lowell
13. Attenuated *Salmonella* Strains as Live Vectors for the Expression of Foreign Antigens 161
Roy Curtiss III
14. Vaccinia as a Live Vector Carrying Cloned Foreign Genes 189
Charles Flexner and Bernard Moss
15. Presentation of Immunogens at the Gut and Other Mucosal Surfaces 207
Nils Y. Lycke and Ann-Mari Svennerholm

Part IV NEW AND IMPROVED VACCINES AGAINST DISEASES FOR WHICH VACCINES ALREADY EXIST

16. New and Improved Vaccines Against Pertussis 231
Erik L. Hewlett and James D. Cherry
17. New and Improved Vaccines Against Diphtheria and Tetanus 251
Rino Rappuoli
18. New and Improved Vaccines Against Typhoid Fever 269
Myron M. Levine, David M. Hone, Bruce A. D. Stocker, and Michel Cadoz
19. New and Improved Vaccines Against Cholera 289
- I. The Oral B Subunit/Inactivated Whole Cell Vaccine 289
Jan Holmgren, Marianne Jertborn, Ann-Mari Svennerholm, David A. Sack, and John D. Clemens
 - II. Attenuated *Vibrio cholerae* Strains Prepared by Recombinant DNA Techniques Used as Live Oral Vaccines 304
James B. Kaper
 - III. Avirulent *Salmonellae* Expressing Cloned *Vibrio* Genes as a Potential Bivalent Typhoid/Cholera Oral Vaccine 311
Paul A. Manning
20. New and Improved Vaccines Against Meningococcal Disease 325
Wendell D. Zollinger

Contents	vii
21. New and Improved Vaccines Against <i>Haemophilus influenzae</i> Type b Infections <i>Porter W. Anderson, Jr.</i>	349
22. New and Improved Vaccines Against Rickettsial Infections: Rocky Mountain Spotted Fever, Epidemic Typhus, and Scrub Typhus <i>Kimberly Weiss and David H. Walker</i>	357
23. New and Improved Vaccines Against Influenza <i>Mary Lou Clements</i>	375
24. New and Improved Vaccines Against Poliomyelitis <i>Philip D. Minor and Jeffrey W. Almond</i>	401
25. New and Improved Vaccines Against Rabies <i>Esteban Celis, Charles E. Rupprecht, and Stanley A. Plotkin</i>	419
26. New and Improved Vaccines Against Hepatitis B	439
I. Recombinant-Derived Hepatitis B Vaccine <i>Ronald W. Ellis</i>	439
II. Recombinant Adenovirus Vaccines for Hepatitis B Virus <i>John E. Morin, Michael D. Lubeck, Bruce B. Mason, Katherine L. Molnar-Kimber, Surendra K. Dheer, Bheem M. Bhat, Pranab K. Chanda, Robert J. Natuk, Murty V. R. Chengalvala, Satoshi Mizutani, Alan R. Davis, and Paul P. Hung</i>	448
27. New and Improved Vaccines Against Yellow Fever, Japanese Encephalitis, and Dengue <i>Philip K. Russell</i>	459
 Part V VACCINES AGAINST DISEASES FOR WHICH IMMUNOPROPHYLAXIS HAS NOT PREVIOUSLY BEEN AVAILABLE 	
28. Vaccines Against the Sporozoite Stage of <i>Plasmodium falciparum</i>	469
I. <i>P. falciparum</i> Circumsporozoite Synthetic Peptide Vaccine <i>Elizabeth H. Nardin and Ruth S. Nussenzweig</i>	469
II. Recombinant <i>P. falciparum</i> Circumsporozoite Protein <i>James F. Young</i>	482
29. Vaccines Against Asexual Blood Stages of <i>Plasmodium falciparum</i> <i>Robin F. Anders and Graham V. Brown</i>	491
30. Vaccines Against the Sexual Stages of <i>Plasmodium falciparum</i> : Transmission-Blocking Vaccines <i>Richard Carter, Louis H. Miller, Michael F. Good, and David Kaslow</i>	513
31. Vaccines Against Vivax Malaria: DNA Approaches to Sporozoite Vaccines <i>Helen L. Gibson, Ian C. Bathurst, and Philip J. Barr</i>	521
32. Vivax Malaria: Strategies for Vaccine Development Based on the Hepatic, Asexual Erythrocytic, and Sexual Stages <i>Peter H. David, John W. Barnwell, and Kamini N. Mendis</i>	531

33.	Vaccines Against <i>Leishmania</i> <i>Emanuela Handman and Malcolm J. McConville</i>	545
34.	Vaccines Against Gonococcal Infections <i>Gary K. Schoolnik and Timothy A. Mietzner</i>	565
35.	Vaccines Against <i>Streptococcus pyogenes</i> Infections <i>Debra Bessen and Vincent A. Fischetti</i>	599
36.	Vaccines Against Leprosy <i>Vijay L. Mehra, Padmini Salgame, Scott B. Snapper, Laszlo Lugosi, William Jacobs, and Barry R. Bloom</i>	611
37.	Vaccines Against <i>Escherichia coli</i> Urinary Tract Infections <i>Peter O'Hanley</i>	631
38.	Vaccines Against Enterotoxigenic <i>Escherichia coli</i> Infections	649
	I. Vaccines Based Predominantly or Entirely on Antibacterial Immunity <i>Myron M. Levine</i>	649
	II. Synthetic Toxoid Vaccines to Prevent Diarrhea Due to Enterotoxigenic <i>Escherichia coli</i> <i>Frederick A. Klipstein</i>	661
39.	Vaccines Against <i>Shigella</i> Infections	667
	I. Live Oral Vaccines Consisting of <i>Escherichia coli</i> or <i>Salmonella typhi</i> Expressing <i>Shigella</i> Antigens <i>Thomas Larry Hale and Samuel B. Formal</i>	667
	II. Aromatic-Dependent <i>Shigella</i> Strains as Live Oral Vaccines <i>Alf A. Lindberg, Anders Karnell, and Bruce A. D. Stocker</i>	677
	III. Synthetic Peptide Toxoid Vaccines Against Shiga Dysentery <i>Ruth Arnon, Ilana Harari, and Gerald Keusch</i>	688
40.	Vaccines Against <i>Klebsiella</i> and <i>Pseudomonas</i> Infections <i>Alan S. Cross, Jerald C. Sadoff, and Stanley J. Cryz, Jr.</i>	699
41.	Vaccines Against Dental Caries Due to <i>Streptococcus mutans</i> <i>Roy Curtiss III and Suzanne M. Michalek</i>	715
42.	Vaccines Against AIDS	741
	I. An Overview of Approaches to Vaccination Against AIDS <i>Carol O. Tacket</i>	741
	II. Vaccinia Expressing HIV Envelope Antigens as a Candidate Vaccine Against AIDS <i>Shiu-Lok Hu</i>	753
43.	Vaccines Against Rotavirus <i>Jorge Flores and Albert Z. Kapikian</i>	765
44.	Vaccines Against Hepatitis A <i>Philip J. Provost</i>	789
45.	Vaccines Against Varicella Infections <i>Michiaki Takahashi</i>	805

Contents	ix
46. Vaccines Against Lassa Fever <i>Christopher Clegg and Graham Lloyd</i>	813
47. Vaccines Against Herpes Simplex Infections <i>Richard J. Whitley and Bernard Meignier</i>	825
48. Antitumor Vaccines	855
I. Why Cancer Vaccines? <i>Karl Erik Hellström, Ingegerd Hellström, and Shiu-Lok Hu</i>	855
II. Anti-Idiotypic Antibodies as Tumor Vaccines <i>Ingegerd Hellström and Karl Erik Hellström</i>	863
III. Recombinant Vaccinia Virus as an Approach to Tumor Immunotherapy <i>Shiu-Lok Hu, Ingegerd Hellström, and Karl Erik Hellström</i>	870
49. Vaccines to Prevent Pregnancy <i>Vernon C. Stevens and Warren R. Jones</i>	879
50. Vaccines to Prevent Cattle Tick Infestations <i>Gary S. Cobon and Peter Willadsen</i>	901
Part VI COMMERCIAL AND REGULATORY ASPECTS OF VACCINE PRODUCTION AND DISTRIBUTION	
51. Large-Scale Production of Attenuated Bacterial and Viral Vaccines <i>Stanley J. Cryz, Jr., and Reinhard Glück</i>	921
52. Commercial Aspects of the Vaccine Industry <i>John R. Clarke and Ghislaine R. Samwuys</i>	933
<i>Index</i>	951